ResMed Profile

USD 2.04  1.82%

Acquisition by David Pendarvis of 5168 shares of ResMed subject to Rule 16b-3

ResMed insider trading alert for grant of resmed common stock by David Pendarvis, Chief Administrative Officer, on September 22, 2018. This event was filed by Resmed Inc with SEC on 2018-08-16. Statement of changes in beneficial ownership - SEC Form 4. David Pendarvis is currently serves as chief admin. officer, global general counsel and secretary of ResMed [view details]   

ResMed Summary

ResMed (RMD) is traded on New York Stock Exchange in USA. It is located in 9001 Spectrum Center Boulevard and employs 6,000 people. The company currently falls under 'Large-Cap' category with total capitalization of 15.5 B. ResMed runs under Healthcare sector within Medical Instruments & Supplies industry. This company has 142.74 M outstanding shares of which 3.12 M shares are at this time shorted by investors with about 4.77 days to cover shorted positions. RESMED INC has about 188.7 M in cash with 524.3 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32.
Check ResMed Probability Of Bankruptcy

Ownership Allocation (%)

ResMed Target Price Odds Analysis

Odds Below 113.83HorizonTargetOdds Above 113.83
87.69%30 days 113.83 11.91%
Based on normal probability distribution, the odds of ResMed to move above current price in 30 days from now is about 11.91% (This ResMed probability density function shows the probability of ResMed Stock to fall within a particular range of prices over 30 days) .

ResMed Top Holders

ResMed Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Vanguard Group IncCommon Shares14.5 M1.5 B
Capital World InvestorsCommon Shares11.6 M1.2 B
View ResMed Diagnostics

ResMed Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

ResMed Key Fundamentals

ResMed Against Markets

ResMed Current Ratings

ResMed 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for ResMed are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. ResMed operates under Medical Instruments Supplies classification in USA and traded on New York Stock Exchange. It employs 6000 people. more
CEO and DirectorMichael FarrellView All
Thematic Classification
Currently Active Investing Idea
Obamacare Repeal
  Obamacare Repeal
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Medical Equipment
InstrumentUSA Stock View All
RegionNorth America
Business Address9001 Spectrum Center Boulevard
Foreign Associate  Australia
ExchangeNew York Stock Exchange
CIK Number0000943819
IndustryMedical Instruments & Supplies
Phone858 836 5000
CurrencyUSD - US Dollar
Next Fiscal Year EndJune 30, 2020
Most Recent QuarterJune 30, 2018
Last Fiscal Year EndJune 30, 2018
Date Short InterestJuly 13, 2018

Current Sentiment - RMD

ResMed Investor Sentiment

Greater number of Macroaxis users are at this time bullish on ResMed. What is your perspective on investing in ResMed? Are you bullish or bearish?
98% Bullish
2% Bearish

ResMed Directors

ResMed Corporate Directors

John Wareham Independent Director
Ronald Taylor Lead Independent Director
Christopher Roberts Independent Director
Additionally take a look at Your Equity Center. Please also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.